Integra Lifesciences Holdings (IART) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $1.68.
- Integra Lifesciences Holdings' Debt to Equity rose 5033.61% to $1.68 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.68, marking a year-over-year increase of 5033.61%. This contributed to the annual value of $1.07 for FY2024, which is 10317.77% up from last year.
- According to the latest figures from Q3 2025, Integra Lifesciences Holdings' Debt to Equity is $1.68, which was up 5033.61% from $1.63 recorded in Q2 2025.
- In the past 5 years, Integra Lifesciences Holdings' Debt to Equity registered a high of $1.68 during Q3 2025, and its lowest value of $0.43 during Q4 2022.
- In the last 5 years, Integra Lifesciences Holdings' Debt to Equity had a median value of $0.54 in 2023 and averaged $0.76.
- In the last 5 years, Integra Lifesciences Holdings' Debt to Equity tumbled by 2698.67% in 2021 and then surged by 11263.77% in 2025.
- Integra Lifesciences Holdings' Debt to Equity (Quarter) stood at $0.52 in 2021, then fell by 17.15% to $0.43 in 2022, then rose by 23.78% to $0.53 in 2023, then surged by 103.18% to $1.07 in 2024, then surged by 56.69% to $1.68 in 2025.
- Its Debt to Equity was $1.68 in Q3 2025, compared to $1.63 in Q2 2025 and $1.12 in Q1 2025.